Betahistine mesylate Chemical Properties

Melting point:

112°C

storage temp. 

Keep in dark place,Inert atmosphere,Room temperature

solubility 

Very soluble in water, freely soluble in ethanol (96 per cent), very slightly soluble in 2-propanol.

form 

Solid

color 

White to Off-White

Water Solubility 

almost transparency

Stability:

Hygroscopic

CAS DataBase Reference

54856-23-4(CAS DataBase Reference)

Safety Information

RTECS 

UT2970200

HS Code 

2933.39.9200

Toxicity

LD50 orl-rat: 3030 mg/kg NIIRDN 6,750,82

Betahistine mesylate Usage And Synthesis

Chemical Properties

White or almost white, crystalline powder, very hygroscopic.

Uses

Vasodilatator;H1 agonist
Betahistine mesylate is an orally active histamine H1 receptor agonist and a H3 receptor antagonist. Betahistine mesylate is used for the study of rheumatoid arthritis (RA).

Definition

Betahistine mesylate is a histamine analog and H1 receptor agonist that serves as a vasodilator. It is used in MENIERE DISEASE and in vascular headaches but may exacerbate bronchial asthma and peptic ulcers.

Indications

Betahistine mesylate is the mesylate salt form of Betahistine, a histamine analog and H3 receptor agonist that serves as a vasodilator. It is used in MENIERE DISEASE and in vascular headaches but may exacerbate bronchial asthma and peptic ulcers.

Safety Profile

Poison by subcutaneous route.Moderately toxic by ingestion and other routes. Whenheated to decomposition it emits toxic fumes of NOx andSOx.

in vitro

In Vitro: Betahistine mesylate (0-10 μM) inhibits [125I]iodoproxyfan binding to membranes of CHO (rH3(445)R) and CHO (hH3(445)R) cells with IC50 values of 1.9 μM and 3.3 μM, respectively. Lead to Ki values of 1.4 μM and 2.5 μM, respectively.
Betahistine mesylate (0-10 μM) has a regulating function on cAMP formation in CHO (rH3(445)R), CHO (rH3(413)R), and CHO (hH3(445)R) cells. At low concentrations, Betahistine mesylate behaves an apparent inverse agonist, and progressively enhances cAMP formation with EC50 values of 0.1 nM, 0.05 nM and 0.3 nM, respectively. In contrast, at concentrations higher than 10 nM, Betahistine mesylate inhibits cAMP formation with an EC50 value of 0.1 μM in CHO (rH3(445)R) and full agonist activity.

Mode of action

Betahistine is indicated for the treatment of Meniere's disease and other audiovestibular disorders like vertigo and tinnitus. Betahistine is an analogue of histamine and an H1-receptor agonist. Stimulating the H1- receptors in the inner ear causes a vasodilatory effect and increased permeability in the blood vessels, resulting in reduced endolymphatic pressure. Betahistine acts by reducing the asymmetrical functioning of sensory vestibular organs and increasing vestibulocochlear blood flow, decreasing symptoms of vertigo, tinnitus, balance disorders, and hearing loss associated with Meniere's disease. Betahistine also acts as a histamine H3- receptor antagonist which causes an increased output of histamine, increase in the direct H1-agonist activity, and inhibition of the activity of vestibular nuclei, helping to restore proper balance and decrease in vertigo symptoms.

Betahistine mesylate (54856-23-4)Related Product Information

• Isopropylamine
• Methyl acetate
• 2,6-Lutidine
• 4-Dimethylaminopyridine
• Kresoxim-methyl
• Thiophanate-methyl
• Methylparaben
• Betahistine
• Doxazosin mesylate
• Dimethyldimethoxysilane
• Bensulfuron methyl
• Azamethiphos
• 2-Chloro-5-chloromethylpyridine
• Methyl acrylate
• Betahistine dihydrochloride
• 4-Methylpyridine
• METHYL THIOPHENE-2-CARBOXYLATE
• Pefloxacin mesylate